Based on the analysis of Tevogen Bio's profitability, liquidity, and operating efficiency, Tevogen Bio Holdings is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. Key indicators impacting Tevogen Bio's financial strength include:
The essential information of the day-to-day investment outlook for Tevogen Bio includes many different criteria found on its balance sheet. An individual investor should monitor Tevogen Bio's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Tevogen Bio.
Net Income
(70,691.25)
Tevogen
Understanding current and past Tevogen Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Tevogen Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Tevogen Bio's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Tevogen Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tevogen Bio Holdings. Check Tevogen Bio's Beneish M Score to see the likelihood of Tevogen Bio's management manipulating its earnings.
Comparative valuation techniques use various fundamental indicators to help in determining Tevogen Bio's current stock value. Our valuation model uses many indicators to compare Tevogen Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tevogen Bio competition to find correlations between indicators driving Tevogen Bio's intrinsic value. More Info.
Tevogen Bio Holdings is currently regarded as top stock in ebitda category among its peers. It also is currently regarded as top stock in net income category among its peers . At this time, Tevogen Bio's EBITDA is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Tevogen Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Tevogen Bio Holdings Systematic Risk
Tevogen Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tevogen Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Tevogen Bio Holdings correlated with the market. If Beta is less than 0 Tevogen Bio generally moves in the opposite direction as compared to the market. If Tevogen Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tevogen Bio Holdings is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tevogen Bio is generally in the same direction as the market. If Beta > 1 Tevogen Bio moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Tevogen Bio is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Tevogen has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Tevogen Bio's financials are consistent with your investment objective using the following steps:
Review Tevogen Bio's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand Tevogen Bio's liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare Tevogen Bio's financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Tevogen Bio's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Tevogen Bio November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tevogen Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tevogen Bio Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tevogen Bio Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Tevogen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tevogen Bio's daily price indicators and compare them against related drivers.
When running Tevogen Bio's price analysis, check to measure Tevogen Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tevogen Bio is operating at the current time. Most of Tevogen Bio's value examination focuses on studying past and present price action to predict the probability of Tevogen Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tevogen Bio's price. Additionally, you may evaluate how the addition of Tevogen Bio to your portfolios can decrease your overall portfolio volatility.